Results 211 to 220 of about 100,614 (290)

Gemcitabine and chlorotoxin conjugated iron oxide nanoparticles for glioblastoma therapy

, 2015
Qingxin Mu, Guanyou Lin, Victoria K. Patton, Kui Wang, Oliver W. Press, Miqin Zhang   +5 more
openalex   +2 more sources

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

INHBA promotes chemoresistance in pancreatic cancer by enhancing CTPS1 stability and mediating pyrimidine metabolism. [PDF]

Cancer Cell Int
Sun X, Wei Z, Liao X, Zheng D, Li F, Chen L, Gong Y, Ran S, Han X, He Z, Yu C.   +10 more
europepmc   +1 more source

Dataset of Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing® for efficient antitumor activity

Lucía Martín Banderas, E Sáez-Fernández, María Ángeles Holgado Villafuerte, María Matilde Durán Lobato, José Prados, Consolación Melguizo Alonso, José L. Arias   +6 more
openalex   +1 more source

Isoquercetin and Zafirlukast Cooperatively Suppress Tumor Growth and Thromboinflammatory Signaling in a Xenograft Model of Ovarian Cancer

The FASEB Journal, Volume 40, Issue 1, 15 January 2026.
Treatment using either the thiol isomerase inhibitor isoquercetin or zafirlukast lowers tissue factor levels, decreases VEGF, inhibits PD‐L1, and TMEM176B in a xenograft model of ovarian cancer. A combination of the two agents, at threefold lower concentrations than either drug, significantly enhanced the inhibition further, suggesting a dual action of
Justine A. Keovilay, Jason W. Hoskins, Jean‐Pierre Kinet, Thomas C. Lines, Daniel R. Kennedy   +4 more
wiley   +1 more source

Hyperthermic intravesical chemotherapy with gemcitabine versus Bacillus Calmette-Guerin in intermediate- and high-risk non-muscle-invasive bladder cancer. [PDF]

Front Oncol
Yan B, Hu W, Li Y, Feng T, Zhu L, Xu H, Chen S, Qiao Y.   +7 more
europepmc   +1 more source

An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol

, 2019
ManoopS Bhutani, Joseph M. Herman, JasonB. Klapman, Richard Tuli, Ghassan El‐Haddad, Sarah E. Hoffe, F. Wong, Beth Chasen, DavidR Fogelman, SimonK Lo, N. Nissen, AndrewE Hendifar, Gauri R. Varadhachary, Matthew H. G. Katz, WilliamD Erwin, E.J. Koay, EricP Tamm, Ben S. Singh, Rutika Mehta, R.A. Wolff, Ashish Soman, Irina M. Cazacu   +21 more
openalex   +2 more sources

Systemic and local decorin levels mirror the clinical course of pancreatic cancer

The Journal of Pathology: Clinical Research, Volume 12, Issue 1, January 2026.
Abstract Despite significant progress in oncology research, pancreatic cancer remains inherently difficult to treat, and the mechanisms underlying therapeutic resistance remain unresolved. Decorin (DCN), a member of the family of small leucine‐rich proteoglycans, has emerged as a versatile actor in various malignant diseases.
Maja Svensson, Sophie Lehn, Hedda Jacobsen, Sofie Olsson Hau, Göran Jönsson, Kristian Pietras, Karin Jirström   +6 more
wiley   +1 more source

Conversion Surgery after Complete Response to Immune Checkpoint Inhibitor-Based Sequential Chemotherapy for Initially Unresectable Perihilar Cholangiocarcinoma: A Case Report. [PDF]

Surg Case Rep
Tomino T, Sugimachi K, Kakimoto T, Kurihara T, Onishi E, Koga Y, Taguchi K, Sugimoto R, Morita M.   +8 more
europepmc   +1 more source

Reconfigurable Nucleic Acid Nanoparticles with Therapeutic RNAi Responses to Intracellular Disease Markers

Advanced Functional Materials, Volume 36, Issue 5, 15 January 2026.
Many known diseases arise from dysregulated gene expression, and differentially expressed genes can serve as biomarkers to distinguish diseased cells from healthy tissues. In this study, reconfigurable nucleic acid nanoparticles (recNANPs) are introduced that can detect overexpressed cancer biomarkers and subsequently release RNAi inducers to silence ...
Yelixza I. Avila, Anh Ha, Morgan R. Chandler, Nathalia Leal Santos, Taejin Kim, Hannah S. Newton, Marina A. Dobrovolskaia, Kirill A. Afonin   +7 more
wiley   +1 more source